Business
MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot
BALTIMORE, Sept. 18, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"BALTIMORE, Sept. 18, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (\"MIRA\" or the \"Company\"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog named MIRA1a, explored the scientific and social drivers behind its development of MIRA1a today at the Cannabinoid Derived Drug Development Summit. The Company shared data and research that positions MIRA1a as a potential future alternative prescription medication with unique properties not found in THC as well as the potential for fewer side effects.\n\nAs an invited speaker at the 6th Annual Cannabinoid Derived Drug Development Summit held in Boston, Dr. Adam Kaplin, President and Chief Scientific Officer of MIRA Pharmaceuticals, said that Mira1a is a new molecular entity that in pre-clinical studies enhances cognitive performance and diminishes anxiety, while potentially aiding models of neuropathic pain.\n\"Because marijuana often impairs cognition, it can worsen performance in school or at work and make it dangerous to drive,\" said Dr. Kaplin. \"Research and studies have also linked heavy marijuana use in children and adolescents to declines in IQ, and in adults has negative effects on attention, memory, and learning. With one molecular change from THC to Mira1a, we now have an opportunity to have a substantial impact on the future of cannabinoids in healthcare and disease.\"\nDr. Kaplin, previously the Chief Neuropsychiatric Consultant to the Johns Hopkins MS Center of Excellence and the founding Director of the Johns Hopkins Ketamine Clinic, was invited to share the latest pre-clinical research on mice. The results showed that when given MIRA1a, mice doubled their cognitive performance.\n\"Healthcare professionals are increasingly turning to marijuana for the benefits it can provide patients, but for a significant number of patients, the unwanted side effects continue to remove it as a viable option,\" added Erez Aminov, the Chief Executive Officer of Mira Pharmaceuticals.\nFor more information, please reference MIRA's publication, Getting into the weeds on cannabis: Known potential side-effects and toxicity, available on the Company's website at https://www.mirapharmaceuticals.com/mira1a.\nAbout MIRA Pharmaceuticals, Inc.\nMIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a pre-clinical-st...